Discover
ATXS
Astria Therapeutics, Inc.
12.58
2 x 8.95
2 x 16.00
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
12.58 +0.00 (0.00%)
| Ytd | -3.90% | |
| 1y | 66.62% |
12.45
day range
12.59
6.58
52 week range
16.90
| Open | Prev Close | 12.58 | Low | 12.45 | High | 12.59 | Mkt Cap | 538.38M | |
| Vol | 0.00 | Avg Vol | 323.01K | EPS | -2.18 | P/E | N/A | Forward P/E | -5.39 |
| Beta | 0.71 | Short Ratio | 12.52 | Inst. Own | 101.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 10.63 | 200-d Avg | 10.85 | 1yr Est | 26.43 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.42 | -0.42 | N/A | N/A |
| 2024-08-12 | 2024-06 | -0.37 | -0.43 | -0.06 | -16.22% |
| 2024-05-09 | 2024-03 | -0.35 | -0.38 | -0.03 | -8.57% |
| 2024-03-04 | 2023-12 | -0.69 | -0.86 | -0.17 | -24.64% |
| 2023-11-13 | 2023-09 | -0.51 | -0.63 | -0.12 | -23.53% |
| 2023-08-07 | 2023-06 | -0.5 | -0.45 | 0.05 | 10.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-14 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-09-27 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | Wedbush | Upgrade | Outperform | Outperform |
Profile
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-31 | MORABITO CHRISTOPHER | Officer | 0.00 | Sale |
| 2024-01-31 | PERCEPTIVE ADVISORS LLC | Director | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 7.82M | 74.62M | 13.86% |
| 2024-09-29 | Perceptive Advisors Llc | 6.49M | 61.87M | 11.49% |
| 2024-09-29 | RA Capital Management, L.P. | 5.11M | 48.70M | 9.05% |
| 2024-09-29 | Vestal Point Capital, LP | 4.00M | 38.16M | 7.09% |
| 2024-09-29 | Fairmount Funds Management LLC | 3.55M | 33.91M | 6.30% |
| 2024-09-29 | Blackrock Inc. | 3.50M | 33.39M | 6.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.56M | 14.89M | 2.77% |
| 2024-08-30 | Fidelity Small Cap Growth Fund | 1.35M | 12.92M | 2.40% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.16M | 11.04M | 2.05% |
| 2024-10-30 | Fidelity Advisor Biotechnology Fund | 978.74K | 9.34M | 1.73% |
| 2024-08-30 | Fidelity Series Small Cap Opportunities Fund | 824.81K | 7.87M | 1.46% |
| 2024-09-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 613.55K | 5.85M | 1.09% |
Split
| Split | Date |
|---|---|
| 1 : 6 | 2021-08-20 |
| 1 : 10 | 2018-12-31 |